The purpose of this study is to explore the impact of two medications-colchicine and low-dose naltrexone (LDN)-relative to standard of care (SOC) on COVID-19 disease progression to severe/critical illness and/or intubation in patients hospitalized with moderate COVID-19. As researchers have learned, COVID-19's clinical course suggests that the hyperinflammatory response seen in severe/critical cases is involved in the pathogenesis of associated adverse sequelae such as acute respiratory distress syndrome (ARDS), thromboembolic disease, and acute cardiac injury. Given colchicine has demonstrated clinical utility in inflammatory syndromes within these systems (e.g. endothelial/vascular/myocardial), and LDN acts both to boost the immune system, and limit an excessive response; they may prove useful in minimizing the risk of disease progression and associated adverse sequelae.
In December 2019, a novel coronavirus caused a cluster of pneumonia cases in Wuhan, China.
The identified virus was officially named severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) and the associated illness named coronavirus disease (COVID-19) (WHO). In the
months since its discovery, the spread of SARS-CoV-2 has led to tens of millions of cases
worldwide. In the United States alone, there have been over 11.6 million cases of COVID-19,
with over 340,000 attributed deaths reported as of December 31, 2020 (CDC Cases in the US).
Despite the recent availability of a preventative vaccine, there are limited
pharmacotherapeutic treatment options for those with an active infection, the majority of
which remain investigational.
Common symptoms among patients with mild disease include fever, altered senses of smell or
taste, fatigue, or cough. More severe cases of COVID-19 may lead to hypoxemia and pneumonia.
When compared to those with less-severe disease, severe/critical COVID-19 pneumonia generally
results in an increase in circulating proinflammatory chemokines and cytokines. The
SARS-CoV-2 virus has specific structural components (e.g. viroporin E and viroporins 3a and
8A) that have been shown to activate NLRP3 inflammasomes NLRP3 has been found to be a major
pathophysiologic component in developing ARDS; and inflammasome activation along with
subsequent cytokine production is seen with myocardial injury, which may provide mechanistic
insight to SARS-CoV-2's ability to cause cardiac insult. Additionally, aberrant activation of
neutrophils and formation of excessive neutrophil extracellular traps (NETs) were found to be
associated with ARDS, and recently to be the potential central cause of severe/critical
COVID-19.
Treatments that influence neutrophil recruitment to sites of inflammation and
hyper-inflammatory response may prove beneficial for reduction in disease progression,
adverse sequelae, and mortality associated with COVID-19 infections. Agents under
investigation to mitigate this detrimental host response include the IL-6 receptor
antagonists. However, their extreme expense, scarce availability, and high-risk for severe
adverse effects relegate the use of these injectable agents to cases that have already
progressed to critical illness.
Colchicine is an oral anti-inflammatory agent that is relatively inexpensive, readily
available, and has been used for generations. Approved for treatment and prophylaxis of gout
flares and Mediterranean fever, it is also used in a variety of other inflammatory
conditions. Colchicine binds to tubulin causing depolymerization, which interferes with
neutrophil chemotaxis, adhesion, and mobilization to sites of inflammation, and contributes
to reduction in superoxide production; through interference of the NLRP3 inflammasome protein
complex, colchicine inhibits IL-1b, IL-6, and IL-18 production. These are recognized as
playing an important role in acute coronary syndrome, pericarditis, and ARDS. Colchicine also
has an anti-apoptotic action on endothelial cells that may provide benefit in minimizing
extravasation, capillary leak, and therefore progression or development of ARDS. Lastly,
coronavirus replication, virion particle assembly, and subsequent exocytosis from the host
cell, have been shown to rely on cytoplasmic structural proteins (microtubules) for
trafficking during its lifecycle. Disrupting microtubule trafficking has the potential to
interfere with these key viral replication steps, and therefore introduction of a microtubule
depolymerizing agent may help treat a coronavirus infection through decreased viral
replication.
The use of colchicine in patients hospitalized with COVID-19 has been studied in several
small uncontrolled case series and comparative cohort studies, as well as small, randomized
controlled trials. Results have been unanimously favorable thus far, though they have
substantial limitations. Some were performed during local COVID-19 surges, rates of
intubation and mortality were likely inflated as a result, and therefore the benefits of
colchicine may be overestimated.
Most well known as an opioid antagonist, or a treatment for alcohol dependence, naltrexone
also possesses immunomodulatory effects. Seen exclusively at low doses, this attribute is
being employed in the pain community as a novel anti-inflammatory agent that has been shown
to reduce symptom severity in fibromyalgia, Crohn's disease, and multiple sclerosis.
Naltrexone is a 50:50 racemic mixture of both L and R isomers - in theory, these isomers
allow it to act in a dualistic fashion, both boosting the immune system yet limiting an
excessive immune response. The L isomer is a competitive inhibitor of the Mu and Kappa opioid
receptor, resulting in elevated levels of endogenous endorphins and enkephalins, which in
turn, functions as an immune enhancer. The R isomer blocks the toll like receptor and
modulates T and B cell activity; the downstream effects limit the release of inflammatory
cytokines including IL-6, IL-12, TNF alpha, and NF-KB. A study in 2017 demonstrated a
significant reduction in cytokines after eight weeks of therapy in eight female patients.
While preliminary LDN studies demonstrate success in Crohn's disease, multiple sclerosis, and
fibromyalgia, there is still a need for follow-up trials to establish definitive evidence of
benefit. The lack of proprietary value in a generic medication with no industry backing has
hampered widespread adoption and FDA approval. Thus, clinical efficacy data is slowly
forthcoming on LDN. At the same time, the safety profile of naltrexone is well established
and very well tolerated in alcohol use disorder. Considering that is a high-risk population,
and the dose used is significantly higher (25-100mg versus 1-4.5mg for LDN), it stands to
reason that LDN should have little to no toxicity. Hepatic function has to be monitored at
higher doses, and the drug should be stopped if necessary. However, with LDN the majority of
adverse drug effects are constitutional (headache, dizziness, nausea etc.), with no end organ
damage and no evidence for opportunistic infections.
As previously outlined, available evidence demonstrates that excessive immune response in the
form of a "cytokine storm" plays a key role in the pathophysiology of COVID-19 offering this
process as a possible target for drug therapy. Known immunomodulatory effects of LDN suggest
that this drug could be used to reduce this exaggerated immune response. While the efficacy
of LDN is being studied in COVID-19 (NCT04604704, NCT04604678, NCT04365985) in combination
with a nutritional supplement, metformin, and ketamine (respectively), only the latter trial
is recruiting at this time, and none includes colchicine.
The proposed study will investigate whether or not the colchicine and naltrexone (used alone
or in combination) can slow the progression of COVID-19 patients hospitalized with mild
illness. A modified version of the World Health Organization's R&D Blueprint Ordinal Clinical
Scale will be used to assess this outcome. Patients enrolled in the study will follow the
schedule of events outlined below. If randomized to receive study drug (colchicine only,
naltrexone only, or both colchicine and naltrexone) patients will continue to take the
medication until discharge form the hospital (but not more than 28 days).
Baseline Enrollment Information collection
- Inclusion & Exclusion Criteria Assessment
- Informed consent, randomization
- Demographics-Documentation of patient characteristics
- Past medical history-Documentation of diagnoses at baseline
- Documentation of need for supplemental home oxygen therapy at baseline
- Rule out pregnancy for female participants of child-bearing age Clinical Course
Monitoring - Performed daily until discharge
- Safety assessment and reporting-Review of chart for AEs by study staff
- Concomitant medications-Review of medications taken in hospital in addition to study
drugs
- New Drug-Drug Interactions-Assessment of new/updated medications to determine risk of
new drug interactions
- Documentation of Colchicine dose frequency (Daily/BID, with rationale if changed)
- Study Drug Administration-For interventional arms: Documentation of date and time of
study drug administration
- Maximum O2 needs for continuous 12-hour periods beginning at hospital admission
- Tmax-Maximum recorded temperature patient reached during the study day
- Chest imaging (yes/no)-Documentation of whether patient received SOC chest imaging on
study day
- EKG or continuous telemetry (yes/no)-Documentation of whether patient received an SOC
EKG or is on continuous telemetry on study day
- LMWH > 0.5 mg/kg/dose (not cumulative daily dose) or heparin drip?
(yes/no)-Documentation of need for more than .5mg/kg total dose of Low Molecular Weight
Heparin on study day
- Level of care-Documentation of clinical scale score; hospital unit through which patient
is being treated
- Length of hospitalization Mortality-Documentation of patient death at any time during
the hospital stay Laboratory Monitoring
- BNP (B-Type Natriuretic Peptide)-Documented during patient's hospital stay as performed
per SOC
- CBC with differential-Documented during patient's hospital stay as performed per SOC
with supplemental research-only labs added as needed
- C-reactive protein-Documented during patient's hospital stay as performed per SOC with
supplemental research-only labs added as need
- D-dimer-Documented during patient's hospital stay as performed per SOC with supplemental
research-only labs added as need
- Ferritin-Documented during patient's hospital stay as performed per SOC with
supplemental research-only labs added as need
- Hepatic Function Panel-Documented during patient's hospital stay as performed per SOC
with supplemental research-only labs added as need
- Procalcitonin-Documented during patient's hospital stay as performed per SOC -Serum
Creatinine (SCr)-Documented during patient's hospital stay as preformed per SOC/as
needed for research
- Troponin-Documented during patient's hospital stay as performed per SOC up to discharge
Dosing strategy-Colchicine Patients randomized to a colchicine-containing treatment arm will
receive colchicine 0.6 mg twice daily for up to 28 days. On the day of enrollment, provided
the first dose can be given prior to 16:00 that day, patients are eligible to receive two
doses; the second dose will be scheduled for 22:00. Patients experiencing gastrointestinal
side effects (nausea, vomiting, and diarrhea) on twice daily dosing may have the dose
decreased to 0.6 mg daily. Dosing will continue twice daily unless there is a change that
requires a dose adjustment or an exclusion criterion is met. Dosing deviations above the
study protocol will be allowed if medically necessary for the treatment of an additional
indication (e.g. colchicine for viral pericarditis).
Renal dosing:
- CrCl* ≥50 mL/min: colchicine 0.6 mg twice daily
- CrCl* 30-49 mL/min: colchicine 0.6 mg every 24 hours
- CrCl* 11-29 mL/min**: colchicine 0.6 mg every 48 hours
- CrCl* ≤10 mL/min: doses will be held
Drug interactions: To ensure patients are properly screened and identified as
eligible/ineligible with respect to prescribed medications, this research team will identify
a group of study pharmacists and physicians (including the PI, Dr. Daniel Delaney, and a pain
specialist, Dr. Joseph Johnson), who will be available as-needed to field questions regarding
any medications a patient is taking during or prior to their hospital stay that may or may
not preclude study participation.
Drug: Colchicine 0.6 mg
Colchicine is an oral anti-inflammatory agent that is relatively inexpensive, readily available, and has been used for generations. Approved for treatment and prophylaxis of gout flares and Mediterranean fever, it is also used in a variety of other inflammatory conditions (e.g. pericarditis and diffuse vascular inflammation such as Behcet syndrome). Colchicine binds to tubulin causing depolymerization, which interferes with neutrophil chemotaxis, adhesion, and mobilization to sites of inflammation, and contributes to reduction in superoxide production; through interference of the NLRP3 inflammasome protein complex, colchicine inhibits IL-1b, IL-6, and IL-18 production.
For this study, patients enrolled in a colchicine containing arm will receive 0.6mg of colchicine BID (unless renal function/gastrointestinal issues require adjustments described in the protocol)
Other Name: Colcrys
Drug: Naltrexone
Most well known as an opioid antagonist, or a treatment for alcohol dependence, naltrexone also possesses immunomodulatory effects. Seen exclusively at low doses, this attribute is being employed in the pain community as a novel anti-inflammatory agent that has been shown to reduce symptom severity in fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome.
For this study, patients enrolled in a naltrexone-containing arm will take their daily dose of the medication (4.5mg) by oral suspension.
Other Name: Vivitrol
Inclusion Criteria:
1. Male and (non-pregnant, non-breastfeeding) females aged 18 years or older
2. Requiring admission to Methodist or Regions Hospital due to laboratory-confirmed
COVID-19
3. Meets criteria of only up to moderate COVID-19 disease as defined by a clinical score
of 2 or 3 at the time of enrollment, and one or more of the following:
1. Dyspnea limiting usual activities on baseline O2 needs
2. Respiratory rate >/= 30/min on O2 or room air
3. Blood oxygen saturations <94% on room air (or on baseline O2 needs if on
supplemental oxygen prior to presentation at the hospital for a condition
unrelated to COVID-19).
4. Requiring supplemental 02 above baseline needs (i.e. prior to presentation at
hospital)
5. COVID-19 contributed to the current hospital admission, per attending provider's
clinical assessment of the patient.
4. Ability to provide written informed consent, or has identifiable LAR that is able to
do so on the patient's behalf as defined by study protocol, prior to performing study
procedures.
Exclusion Criteria:
1. Patients meeting criteria for severe/critical COVID-19 as defined by study protocol or
requiring O2 supplementation ≥10L nasal cannula at screening
2. Patients currently in shock as defined by hemodynamic instability requiring
vasopressors
3. Patients with a current hospitalization for COVID-19 that is >/=7 days at the time of
screening.
4. Clinical estimation of attending physician that the patient will require mechanical
respiratory support within 48 hours of enrollment
5. Patients in which EITHER symptom onset OR a positive COVID-19 laboratory test occurred
>14 days prior to enrollment.
6. Patients with concomitant influenza A or B at time of hospitalization if tested as
part of ED/hospital admission.
7. Female patients who are pregnant or breastfeeding at time of hospital admission
8. Diagnosis of Chronic Kidney Disease stage ≥4 as documented in the patient's problem
list (not based on CrCI calculations alone)
9. CrCl < 30 mL/min or requiring renal replacement therapy (e.g. intermittent
hemodialysis, continuous renal replacement therapy, peritoneal dialysis) at screening
10. History of cirrhosis or advanced liver disease, or active hepatic viral infection
11. Transplant of kidney, lung, heart, or liver in the past 2 years
12. Uncontrolled severe gastrointestinal disorders, Crohn's disease, ulcerative colitis,
chronic diarrhea, diarrhea predominant irritable bowel syndrome, active stomach or
intestinal ulcer, or one that was treated within the last 6 months
13. Patients currently receiving agents that are p-glycoprotein AND strong CYP3A4
inhibitors with CrCl < 60 mL/min, or any combination of drug interactions that is not
amenable to dosage adjustment (refer to list of medications with potential Colchicine
and Naltrexone interactions).
14. Patients actively undergoing chemotherapy for an active malignancy, or history of a
hematologic malignancies
15. Chronic or current use of colchicine or any mu-opioid antagonist.
16. Chronic, scheduled opioid therapy (i.e. not intermittent as needed use), or, prior to
enrollment, an acute condition requiring continued pain control that is unattainable
without ongoing opioid therapy.
17. Pre-existing condition that is being treated with tocilizumab, anakinra, sarilumab,
other interleukin-antagonists, TNF-inhibitors, or JAK inhibitors.
18. NOTE: Patients treated with tocilizumab will be permitted to enroll if their care team
is prescribing it for COVID-19. Use of tocilizumab at baseline for another indication
will continue to be excluded.
19. Participation in any other clinical trial of an experimental treatment for COVID-19,
note:
1. While convalescent plasma is no longer recommended within HP, it can be given if
deemed appropriate by the medical team once ≥ 24 hours has elapsed since
enrollment;
2. Patients previously enrolled in the C3PO study can enroll in this study, as any
convalescent plasma received would have been outpatient;
3. Remdesivir is allowed per standard protocol;
4. Dexamethasone is allowed per standard protocol
20. Patients actively enrolled in hospice or that are DNI or on palliative care
21. History of hypersensitivity reaction to colchicine or its inactive ingredients
22. History of hypersensitivity reaction to naltrexone or its inactive ingredients
23. Incarcerated or a ward of the state
24. Any patient considered an unsuitable candidate, for any reason, by study
investigators.
Park Nicollet Methodist Hospital
Saint Louis Park, Minnesota, United States
Regions Hospital
Saint Paul, Minnesota, United States
Dan Delaney, PharmD, Principal Investigator
Park Nicollet Methodist Hospital